The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients

M. Asghar Pasha, David Jourd'Heuil, Francis Jourd'Heuil, Lori Mahon, Francisco Romero, Paul J. Feustel, Mary Evans, Thomas Smith, Jesse Mitchell, Pradeep Gendapodi, Kelly C. DeMeyere-Coursey, Robert G. Townley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Measurement of fractional nitric oxide concentration in exhaled breath (FENO) is a simple, noninvasive method to evaluate eosinophilic airway inflammation. Nitric oxide (NO) arising from peripheral small airways/alveoli (alveolar NO concentration [CalvNO]) can be estimated using multiple flow rates and a two-compartment model of the airways and alveoli. Omalizumab, a monoclonal anti-IgE antibody, is approved for the treatment of allergic asthma and also has been shown to decrease FENO levels. This study investigates the effects of omalizumab, when added to an inhaled corticosteroid (ICS) ± long-acting beta-adrenergic agonist (LABA) treatment, on peripheral small airway/alveolar inflammation reflected by FE NO measurements at higher flow rates. We hypothesized that compared with placebo, omalizumab would decrease CalvNO levels in asthmatic patients on ICS ± LABA. Forty-two patients with moderate-to-severe asthma were randomly assigned 2:1 to either omalizumab (n = 29) or placebo treatment (n = 13) for 16 weeks. Selection criteria included moderate-to-severe asthmatic patients on an ICS ± LABA, positive skin test to one or more perennial allergen, screening FENO of >13 ppb, and a baseline IgE of 30-700 IU/mL. FENO measured at multiple flow rates was used to calculate CalvNO over the course of 16 weeks. FENO levels decrease with increasing flow rates (p <0.05 repeated measures ANOVA) but no differences between the placebo and treatment groups in overall CalvNO levels or in the changes of CalvNO with time were found. Omalizumab did not lower the CalvNO, which could have been caused by the initial low CalvNO in this asthmatic population. The model used may not be completely sufficient and/or sensitive enough to detect small changes in CalvNO.

Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalAllergy and Asthma Proceedings
Volume35
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Nitric Oxide
Adrenergic beta-Agonists
Inflammation
Adrenal Cortex Hormones
Placebos
Asthma
Therapeutics
Skin Tests
Allergens
Immunoglobulin E
Patient Selection
Analysis of Variance
Monoclonal Antibodies
Omalizumab
Population

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Pasha, M. A., Jourd'Heuil, D., Jourd'Heuil, F., Mahon, L., Romero, F., Feustel, P. J., ... Townley, R. G. (2014). The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients. Allergy and Asthma Proceedings, 35(3), 241-249. https://doi.org/10.2500/aap.2014.35.3741

The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients. / Pasha, M. Asghar; Jourd'Heuil, David; Jourd'Heuil, Francis; Mahon, Lori; Romero, Francisco; Feustel, Paul J.; Evans, Mary; Smith, Thomas; Mitchell, Jesse; Gendapodi, Pradeep; DeMeyere-Coursey, Kelly C.; Townley, Robert G.

In: Allergy and Asthma Proceedings, Vol. 35, No. 3, 2014, p. 241-249.

Research output: Contribution to journalArticle

Pasha, MA, Jourd'Heuil, D, Jourd'Heuil, F, Mahon, L, Romero, F, Feustel, PJ, Evans, M, Smith, T, Mitchell, J, Gendapodi, P, DeMeyere-Coursey, KC & Townley, RG 2014, 'The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients', Allergy and Asthma Proceedings, vol. 35, no. 3, pp. 241-249. https://doi.org/10.2500/aap.2014.35.3741
Pasha, M. Asghar ; Jourd'Heuil, David ; Jourd'Heuil, Francis ; Mahon, Lori ; Romero, Francisco ; Feustel, Paul J. ; Evans, Mary ; Smith, Thomas ; Mitchell, Jesse ; Gendapodi, Pradeep ; DeMeyere-Coursey, Kelly C. ; Townley, Robert G. / The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients. In: Allergy and Asthma Proceedings. 2014 ; Vol. 35, No. 3. pp. 241-249.
@article{8d26f47e625e44b881993471bf396689,
title = "The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients",
abstract = "Measurement of fractional nitric oxide concentration in exhaled breath (FENO) is a simple, noninvasive method to evaluate eosinophilic airway inflammation. Nitric oxide (NO) arising from peripheral small airways/alveoli (alveolar NO concentration [CalvNO]) can be estimated using multiple flow rates and a two-compartment model of the airways and alveoli. Omalizumab, a monoclonal anti-IgE antibody, is approved for the treatment of allergic asthma and also has been shown to decrease FENO levels. This study investigates the effects of omalizumab, when added to an inhaled corticosteroid (ICS) ± long-acting beta-adrenergic agonist (LABA) treatment, on peripheral small airway/alveolar inflammation reflected by FE NO measurements at higher flow rates. We hypothesized that compared with placebo, omalizumab would decrease CalvNO levels in asthmatic patients on ICS ± LABA. Forty-two patients with moderate-to-severe asthma were randomly assigned 2:1 to either omalizumab (n = 29) or placebo treatment (n = 13) for 16 weeks. Selection criteria included moderate-to-severe asthmatic patients on an ICS ± LABA, positive skin test to one or more perennial allergen, screening FENO of >13 ppb, and a baseline IgE of 30-700 IU/mL. FENO measured at multiple flow rates was used to calculate CalvNO over the course of 16 weeks. FENO levels decrease with increasing flow rates (p <0.05 repeated measures ANOVA) but no differences between the placebo and treatment groups in overall CalvNO levels or in the changes of CalvNO with time were found. Omalizumab did not lower the CalvNO, which could have been caused by the initial low CalvNO in this asthmatic population. The model used may not be completely sufficient and/or sensitive enough to detect small changes in CalvNO.",
author = "Pasha, {M. Asghar} and David Jourd'Heuil and Francis Jourd'Heuil and Lori Mahon and Francisco Romero and Feustel, {Paul J.} and Mary Evans and Thomas Smith and Jesse Mitchell and Pradeep Gendapodi and DeMeyere-Coursey, {Kelly C.} and Townley, {Robert G.}",
year = "2014",
doi = "10.2500/aap.2014.35.3741",
language = "English",
volume = "35",
pages = "241--249",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "3",

}

TY - JOUR

T1 - The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients

AU - Pasha, M. Asghar

AU - Jourd'Heuil, David

AU - Jourd'Heuil, Francis

AU - Mahon, Lori

AU - Romero, Francisco

AU - Feustel, Paul J.

AU - Evans, Mary

AU - Smith, Thomas

AU - Mitchell, Jesse

AU - Gendapodi, Pradeep

AU - DeMeyere-Coursey, Kelly C.

AU - Townley, Robert G.

PY - 2014

Y1 - 2014

N2 - Measurement of fractional nitric oxide concentration in exhaled breath (FENO) is a simple, noninvasive method to evaluate eosinophilic airway inflammation. Nitric oxide (NO) arising from peripheral small airways/alveoli (alveolar NO concentration [CalvNO]) can be estimated using multiple flow rates and a two-compartment model of the airways and alveoli. Omalizumab, a monoclonal anti-IgE antibody, is approved for the treatment of allergic asthma and also has been shown to decrease FENO levels. This study investigates the effects of omalizumab, when added to an inhaled corticosteroid (ICS) ± long-acting beta-adrenergic agonist (LABA) treatment, on peripheral small airway/alveolar inflammation reflected by FE NO measurements at higher flow rates. We hypothesized that compared with placebo, omalizumab would decrease CalvNO levels in asthmatic patients on ICS ± LABA. Forty-two patients with moderate-to-severe asthma were randomly assigned 2:1 to either omalizumab (n = 29) or placebo treatment (n = 13) for 16 weeks. Selection criteria included moderate-to-severe asthmatic patients on an ICS ± LABA, positive skin test to one or more perennial allergen, screening FENO of >13 ppb, and a baseline IgE of 30-700 IU/mL. FENO measured at multiple flow rates was used to calculate CalvNO over the course of 16 weeks. FENO levels decrease with increasing flow rates (p <0.05 repeated measures ANOVA) but no differences between the placebo and treatment groups in overall CalvNO levels or in the changes of CalvNO with time were found. Omalizumab did not lower the CalvNO, which could have been caused by the initial low CalvNO in this asthmatic population. The model used may not be completely sufficient and/or sensitive enough to detect small changes in CalvNO.

AB - Measurement of fractional nitric oxide concentration in exhaled breath (FENO) is a simple, noninvasive method to evaluate eosinophilic airway inflammation. Nitric oxide (NO) arising from peripheral small airways/alveoli (alveolar NO concentration [CalvNO]) can be estimated using multiple flow rates and a two-compartment model of the airways and alveoli. Omalizumab, a monoclonal anti-IgE antibody, is approved for the treatment of allergic asthma and also has been shown to decrease FENO levels. This study investigates the effects of omalizumab, when added to an inhaled corticosteroid (ICS) ± long-acting beta-adrenergic agonist (LABA) treatment, on peripheral small airway/alveolar inflammation reflected by FE NO measurements at higher flow rates. We hypothesized that compared with placebo, omalizumab would decrease CalvNO levels in asthmatic patients on ICS ± LABA. Forty-two patients with moderate-to-severe asthma were randomly assigned 2:1 to either omalizumab (n = 29) or placebo treatment (n = 13) for 16 weeks. Selection criteria included moderate-to-severe asthmatic patients on an ICS ± LABA, positive skin test to one or more perennial allergen, screening FENO of >13 ppb, and a baseline IgE of 30-700 IU/mL. FENO measured at multiple flow rates was used to calculate CalvNO over the course of 16 weeks. FENO levels decrease with increasing flow rates (p <0.05 repeated measures ANOVA) but no differences between the placebo and treatment groups in overall CalvNO levels or in the changes of CalvNO with time were found. Omalizumab did not lower the CalvNO, which could have been caused by the initial low CalvNO in this asthmatic population. The model used may not be completely sufficient and/or sensitive enough to detect small changes in CalvNO.

UR - http://www.scopus.com/inward/record.url?scp=84899816592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899816592&partnerID=8YFLogxK

U2 - 10.2500/aap.2014.35.3741

DO - 10.2500/aap.2014.35.3741

M3 - Article

VL - 35

SP - 241

EP - 249

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 3

ER -